Karen E. Beenken

Dr. Karen E. Beenken

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in World Journal of Orthopedics
Verified
Journal Article
Open access
Jessica JenningsJessica Jennings
Jessica Jennings
KBKaren E. Beenken
Karen E. Beenken
RSRobert A Skinner
Robert A Skinner
DMDaniel G Meeker
Daniel G Meeker
MSMark S Smeltzer
Mark S Smeltzer
KTKaren S Troxel
Karen S Troxel
Antibiotic-loaded phosphatidylcholine inhibits staphylococcal bone infection

13 May 2021 in Scientific Reports
Verified
Journal Article
Open access
PDF file
KBKaren E. Beenken
Karen E. Beenken
MCMara J. Campbell
Mara J. Campbell
ARAura M. Ramirez
Aura M. Ramirez
KAKarrar Alghazali
Karrar Alghazali
CWChristopher M. Walker
Christopher M. Walker
MSMark S Smeltzer
Mark S Smeltzer
We previously reported the development of an osteogenic bone filler scaffold consisting of degradable polyurethane, hydroxyapatite, and decellularized bovine bone particles. The current study was aimed at evaluating the use of this scaffold as a means of local antibiotic delivery to prevent infection in a bone defect contaminated with Staphylococcus aureus. We evaluated two scaffold formulations with the same component ratios but differing overall porosity and surface area. Studies with vancomycin, daptomycin, and gentamicin confirmed that antibiotic uptake was concentration dependent and that increased porosity correlated with increased uptake and prolonged antibiotic release. We also demonstrate that vancomycin can be passively loaded into either formulation in sufficient concentration to prevent infection in a rabbit model of a contaminated segmental bone defect. Moreover, even in those few cases in which complete eradication was not achieved, the number of viable bacteria in the bone was significantly reduced by treatment and there was no radiographic evidence of osteomyelitis. Radiographs and microcomputed tomography (µCT) analysis from the in vivo studies also suggested that the addition of vancomycin did not have any significant effect on the scaffold itself. These results demonstrate the potential utility of our bone regeneration scaffold for local antibiotic delivery to prevent infection in contaminated bone defects.

9 April 2025 in Microorganisms
Verified
Journal Article
Open access
PDF file
KBKaren E. Beenken
Karen E. Beenken
MSMark S Smeltzer
Mark S Smeltzer
Staphylococcus aureus is one of the most diverse bacterial pathogens. This is reflected in its ability to cause a wide array of infections and in genotypic and phenotypic differences between clinical isolates that extend beyond their antibiotic resistance status. Many S. aureus infections, including those involving indwelling medical devices, are therapeutically defined by the formation of a biofilm. This is reflected in the number of reports focusing on S. aureus biofilm formation and biofilm-associated infections. These infections are characterized by a level of intrinsic resistance that compromises conventional antibiotic therapy irrespective of acquired resistance, suggesting that an inhibitor of biofilm formation would have tremendous clinical value. Many reports have described large-scale screens aimed at identifying compounds that limit S. aureus biofilm formation, but relatively few examined whether the limitation was sufficient to overcome this intrinsic resistance. Similarly, while many of these reports examined the impact of putative inhibitors on S. aureus phenotypes, very few took a focused approach to identify and optimize an effective inhibitor of specific biofilm-associated targets. Such approaches are dependent on validating a target, hopefully one that is not restricted by the diversity of S. aureus as a bacterial pathogen. Rigorous biological validation of such a target would allow investigators to virtually screen vast chemical libraries to identify potential inhibitors that warrant further investigation based on their predicted function. Here, we summarize reports describing S. aureus regulatory loci implicated in biofilm formation to assess whether they are viable targets for the development of an anti-biofilm therapeutic strategy with an emphasis on whether sarA has been sufficiently validated to warrant consideration in this important clinical context.

31 January 2025 in Infection and Immunity
Verified
Journal Article
Open access
KBKaren E. Beenken
Karen E. Beenken
MCMara J. Campbell
Mara J. Campbell
MSMark S Smeltzer
Mark S Smeltzer
We demonstrate that mutation of the staphylococcal accessory regulator A ( sarA ) in the USA300 strain LAC limits virulence in a murine osteomyelitis model to a greater extent than mutation of the accessory gene regulator ( agr ) and that it does so irrespective of the functional status of agr . Protease production was decreased in the agr mutant but increased in sarA and sarA/agr mutants to a degree that limited biofilm formation. Extracellular protein A (eSpa) and full-length extracellular nuclease (Nuc1) were absent in the conditioned medium (CM) from sarA and sarA / agr mutants, and their abundance was restored in both mutants by eliminating protease production. Cytotoxicity of CM for osteoblasts and osteoclasts was also reduced in both mutants. Cytotoxicity was restored in a protease-deficient sarA mutant but not in the protease-deficient sarA / agr mutant. Reduced cytotoxicity was correlated with the reduced abundance of full-length α-toxin, LukF, and LukS in sarA and sarA / agr mutants. The abundance of these toxins in their full-length form was increased in the protease-deficient sarA mutant by comparison to LAC, demonstrating that mutation of sarA increases the production of these toxins but increased protease production limits their abundance in full-length and presumably functional forms. Most importantly, eliminating protease production enhanced the virulence of sarA and sarA/agr mutants, but had no impact in the agr mutant. We conclude that a key factor in the attenuation of LAC sarA and sarA / agr mutants in osteomyelitis is the increased production of extracellular proteases and its impact on virulence factors that contribute to biofilm formation and cytotoxicity. IMPORTANCE: The persistent emergence of antibiotic-resistant strains has rekindled interest in anti-virulence strategies to combat S. aureus infections. Numerous reports describe anti-virulence strategies focusing on key regulatory elements that globally influence virulence factor production, the two most commonly targeted being the accessory gene regulator ( agr ) and the staphylococcal accessory regulator A ( sarA ). We demonstrate that mutation of sarA limits virulence to a greater extent than mutation of agr and that this can be attributed to increased protease production in both sarA and sarA / agr mutants. This illustrates the critical role of sarA in protease-mediated post-translational regulation in S. aureus . It also suggests that an inhibitor of sarA would be more effective than an inhibitor of agr in overcoming the therapeutic recalcitrance of osteomyelitis and that such an inhibitor would remain effective even in the context of agr mutants known to arise in vivo during the transition from acute to chronic infection.

11 June 2026 in Clinical Microbiology Reviews
Verified
Journal Article
Closed access
KBKaren E. Beenken
Karen E. Beenken
MCMara J. Campbell
Mara J. Campbell
HRHumberto Reyes-Pardo
Humberto Reyes-Pardo
COCharles A. O’BRien
Charles A. O’BRien
MSMark S Smeltzer
Mark S Smeltzer
SUMMARY: Osteomyelitis refers to inflammation in the bone and is most often a consequence of bacterial infection. The most common cause, and the pathogen that causes the most severe form of infection, is Staphylococcus aureus. S. aureus is a common commensal of healthy humans, and this contributes to its predominance as a cause of osteomyelitis, but this does not account for the severity of S. aureus bone infections or their therapeutic recalcitrance to conventional antibiotic therapy. Clinical characteristics of osteomyelitis implicated in this regard include cortical bone destruction resulting in a compromised local blood supply, formation of a biofilm, the ability to invade and survive inside osteoblasts, osteoclasts, and osteocytes, the formation of small-colony variants and persister cells, and invasion of the osteocyte lacuno-canalicular network. This review summarizes evidence implicating these features in the pathogenesis and therapeutic recalcitrance of osteomyelitis, and the attributes of S. aureus that contribute to these features and define S. aureus as the predominant orthopedic pathogen.

16 January 2025 in Microorganisms
Verified
Journal Article
Open access
PDF file
KBKaren E. Beenken
Karen E. Beenken
MCMara J. Campbell
Mara J. Campbell
SBStephanie Byrum
Stephanie Byrum
RERick D. Edmondson
Rick D. Edmondson
SMSamuel G. Mackintosh
Samuel G. Mackintosh
MSMark S Smeltzer
Mark S Smeltzer
Using a murine osteomyelitis model, we recently demonstrated that Staphylococcus aureus sarA and sarA/agr mutants generated in the USA300 strain LAC are attenuated to a greater extent than an isogenic agr mutant and that this can be attributed to a significant extent to the increased production of extracellular proteases in both mutants. Based on this, we used a mass-based proteomics approach to compare the proteomes of LAC, its isogenic agr, sarA, and sarA/agr mutants, and isogenic derivatives of all four of these strains unable to produce the extracellular proteases aureolysin, SspA, SspB, ScpA, or SplA-F. This allowed us to identify proteins that were present in reduced amounts in sarA, and sarA/agr mutants owing to the increased production of extracellular proteases. A total of 1039 proteins were detected in conditioned media (CM) from overnight cultures of LAC, and protease-mediated degradation was shown to contribute to the reduced abundance of 224 of these (21.6%) in CM from the sarA and sarA/agr mutants. Among these were specific proteins previously implicated in the pathogenesis and therapeutic recalcitrance of S. aureus osteomyelitis. This demonstrates that the ability of sarA to limit protease production plays a key role in post-translational remodeling of the S. aureus proteome to a degree that can be correlated with reduced virulence in our osteomyelitis model, and that it does so irrespective of the functional status of agr. This also suggests that at least some of these 224 proteins may be viable targets for prophylactic or therapeutic intervention.